


SSTR5 antagonist 2

Cat. No.:	HY-114191
CAS No.:	1254730-81-8
Molecular Formula:	C ₃₂ H ₃₅ FN ₂ O ₅
Molecular Weight:	546.63
Target:	Somatostatin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (45.73 mM); ultrasonic and warming and heat to 60°C				
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	
				5 mg	
				10 mg	
				10 mM	
			1 mg	5 mg	10 mg
	1 mM		1.8294 mL	9.1470 mL	18.2939 mL
	5 mM		0.3659 mL	1.8294 mL	3.6588 mL
	10 mM		0.1829 mL	0.9147 mL	1.8294 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) ^[1] .
IC ₅₀ & Target	SSTR5 ^[1] .
In Vivo	SSTR5 antagonist 2 (10 mg/kg, orally) increases both total and active circulating incretin hormone GLP1 levels in mice at a dose of 10 mg/kg ^[1] . SSTR5 antagonist 2 increases pancreatic insulin secretion as well as total and active GLP1 release, and demonstrates synergistic effects in combination with DPP4 inhibitors ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rodent diabetic model without risk of hypoglycemia ^[1] .
Dosage:	10 mg/kg.
Administration:	Orally.
Result:	Increased both total and active circulating incretin hormone GLP1 levels.

REFERENCES

[1]. Liu W, et al. Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition. ACS Med Chem Lett. 2018 Sep 12;9(11):1082-1087.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA